KSP-0243
/ Kissei
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 17, 2025
An Early Phase 2 Clinical Study of KSP-0243
(clinicaltrials.gov)
- P2 | N=108 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Oct 2024 | Trial primary completion date: Mar 2025 ➔ Oct 2024
Trial completion • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
November 28, 2024
A Phase IIa, randomized, double-blind, placebo-controlled, multicentre study of a once daily multiple oral administration of KSP-0243 in patients with mild-to-moderate ulcerative colitis
(clinicaltrialsregister.eu)
- P2 | N=30 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd.
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
July 23, 2024
An Early Phase 2 Clinical Study of KSP-0243
(clinicaltrials.gov)
- P2 | N=100 | Active, not recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
May 26, 2023
An Early Phase 2 Clinical Study of KSP-0243
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
April 26, 2023
An Early Phase 2 Clinical Study of KSP-0243
(clinicaltrials.gov)
- P2 | N=100 | Not yet recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd.
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 5
Of
5
Go to page
1